Activity of Interferon-α and Isotretinoin in Patients with Advanced, Refractory Lymphoid Malignancies

Cancer

Volumn 100, Issue 3, 2004, Pages 574-580

  Tsimberidou, Apostolia Maria ^a   Giles, Francis ^a   Romaguera, Jorge ^a   Duvic, Madeleine ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Hodgkin disease; Interferon ; Lymphoma; Mycosis fungoides; Retinoids

Indexed keywords

ALPHA INTERFERON; BETA 2 MICROGLOBULIN; BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; GEMFIBROZIL; IFOSFAMIDE; ISOTRETINOIN; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PENTOSTATIN; PREDNISONE; PROCARBAZINE; RECOMBINANT ALPHA2B INTERFERON; THIOMALATE SODIUM; TRIACYLGLYCEROL; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHEILITIS; CHILL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONJUNCTIVITIS; DEPRESSION; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GRANULOCYTOPENIA; HAIR DISEASE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HODGKIN DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; LIVER TOXICITY; LYMPHOMA; MALE; MELENA; MOOD DISORDER; MYALGIA; NAUSEA AND VOMITING; OUTCOMES RESEARCH; PANCREATITIS; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN DISEASE; SKIN MANIFESTATION; SOMNOLENCE; T CELL LYMPHOMA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; INTERFERON-ALPHA; ISOTRETINOIN; LYMPHOMA, NON-HODGKIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 1642494642     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20009     Document Type: Article

References (35)

1. Fisher RI. Overview of non-Hodgkin's lymphoma: biology, staging, and treatment. Semin Oncol. 2003;30(Suppl. 4): 3-9.
2. McLaughlin P. The role of interferon in the therapy of malignant lymphoma. Biomed Pharmacother. 1996;50:140-148.
3. Leavitt RD, Ratanatharathorn V, Ozer H, et al. Alfa-2b interferon in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol. 1987;14(2 Suppl 2):18-23.
4. Koziner B. Alpha interferon in patients with progressive and/or recurrent Hodgkin's disease. Eur J Cancer. 1991;27(Suppl 4):S79-80.
5. Redman J, Hagemeister F, McLaughlin P, et al. Alpha-interferon treatment of Hodgkin's disease [abstract]. Proc Am Soc Clin Oncol. 1990;9:256.
6. Horning SJ, Merigan TC, Krown SE, et al. Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial. Cancer. 1985;56:1305-1310.
7. Molin L, Thomsen K, Volden G, et al. Oral retinoids in mycosis fungoides and Sezary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol (Stockh). 1987;67:232-236.
8. Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR, Meyskens FL, Jr. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol. 1987;123:201-204.
9. Kessler JF, Meyskens FL Jr., Levine N, Lynch PJ, Jones SE. Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. Lancet. 1983;1:1345-1347.
10. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19:2456-2471.
11. Cheng AL, Su IJ, Chen CC, et al. Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study. J Clin Oncol. 1994;12:1185-1192.
12. Knobler RM, Trautinger F, Radaszkiewicz T, Kokoschka EM, Micksche M. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol. 1991;24(2 Pt 1):247-252.
13. Thestrup-Pedersen K, Hammer R, Kaltoft K, Sogaard H, Zachariae H. Treatment of mycosis fungoides with recombinant interferon-alpha 2a2 alone and in combination with etretinate. Br J Dermatol. 1988;118:811-818.
14. Dreno B, Claudy A, Meynadier J, et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate. Br J Dermatol. 1991;125:456-459.
15. Zachariae H, Thestrup-Pedersen K. Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma. J Invest Dermatol. 1990;95(6 Suppl):206S-208S.
16. Duvic M, Lemak NA, Redman JR, et al. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996;34:1022-1029.
17. Aviles A, Guzman R, Garcia EL, Diaz-Maqueo JC. Biological modifiers (etretinate [changed from etetrinatel and alfa 2a) in the treatment of refractory cutaneous T-cell lymphoma. Cancer Biother Radiopharm. 1996;11:21-24.
18. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med. 1987;316:297-303.
19. National Cancer Institute. The revised common toxicity criteria, version 2.0. Available from URL: http://ctep.info.nih. gov [accessed 24 November 2003].
20. Dixon DO, McLaughlin P, Hagemeister FB, et al. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol. 1987;5:1670-1672.
21. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
22. Bunn PA Jr., Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med. 1994;121:592-602.
23. Moore DM, Kalvakolanu DV, Lippman SM, et al. Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Semin Hematol. 1994;31(4 Suppl 5):31-37.
24. Bollag W. Retinoids and interferon: a new promising combination? Br J Haematol. 1991;79(Suppl 1):87-91.
25. Matikainen S, Ronni T, Hurme M, Pine R, Julkunen I. Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells. Blood. 1996;88:114-123.
26. Peck R, Bollag W. Potentiation of retinoid-induced differentiation of HL-60 and U937 cell lines by cytokines. Eur J Cancer. 1991;27:53-57.
27. Chen GS, Chang YF, Chang MC, Tsan KW. Response of Epstein-Barr virus-associated Ki-1+ anaplastic large cell lymphoma to 13-cis retinoic acid and interferon alpha. J Formos Med Assoc. 1998;97:420-424.
28. Ong C, Sullivan J, Hertzberg M, Stapleton K. Stage IV CD30+ anaplastic large cell lymphoma: response to acitretin and interferon-alpha. Australas J Dermatol. 2002;43:207-210.
29. Bunn PA Jr., Foon KA, Ihde DC, et al. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med. 1984;101:484-487.
30. Foon KA, Roth MS, Bunn PA Jr. Interferon therapy of non-Hodgkin's lymphoma. Cancer. 1987;59(3 Suppl):601-604.
31. Kohn EC, Steis RG, Sausville EA, et al. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sezary syndrome. J Clin Oncol. 1990;8:155-160.
32. Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol. 1989;20:395-407.
33. VanderMolen LA, Steis RG, Duffey PL, et al. Low-versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma. J Natl Cancer Inst. 1990;82:235-238.
34. Cheng AL, Chuang SE, Su IJ. Factors associated with the therapeutic efficacy of retinoic acids on malignant lymphomas. J Formos Med Assoc. 1997;96:525-534.
35. Brown RE, Nazmi RK. The Reed-Steinberg cell: molecular characterization by proteomic analysis with therapeutic implications. Ann Clin Lab Sci. 2002;32:339-351.